BiotechTubeBiotechTube
Home/CAMP4 Therapeutics/Joshua Mandel-Brehm, J.D.
JM

Joshua Mandel-Brehm, J.D.

President, Chief Executive Officer, and Board Member

CAMP4 Therapeutics

Therapeutic Areas

NeurologyMetabolic DisordersRare Diseases

CAMP4 Therapeutics Pipeline

DrugIndicationPhase
Undisclosed PRAM (SCN1A-targeting)Dravet SyndromePreclinical
Undisclosed PRAM (CDKL5-targeting)CDKL5 Deficiency DisorderPreclinical
Undisclosed PRAM (OTC-targeting)Ornithine Transcarbamylase (OTC) DeficiencyPreclinical

Leadership Team at CAMP4 Therapeutics

MH
Michael H. Brodsky
Chief Scientific Officer and Board Observer
VS
Vivian S. Lee, M.D., Ph.D.
Chief Medical Officer
GF
Gregory F. Covino, CPA
Chief Financial Officer
RA
Richard A. Young, Ph.D.
Scientific Co-Founder, Professor at MIT, Member of Whitehead Institute
DM
David M. Bartel, Ph.D.
Scientific Co-Founder, Professor at MIT, HHMI Investigator
View full CAMP4 Therapeutics profile